Loading...
Market
Annual revenue from Tagrisso for EGFR-mutated lung cancer by end of 2024
5
Resolution / Starting Odds
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
AstraZeneca financial reports, official press releases
Story
AstraZeneca's Tagrisso Shows 84% Reduction in Disease Progression in Trials
Jun 2, 2024, 01:30 PM
Tagrisso, one of AstraZeneca's drugs, greatly slowed cancer progression for patients with stage 3 lung cancer, particularly those with a specific genetic mutation, achieving a major PFS benefit (HR=0.16). The drug reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer compared to a placebo in the LAURA Phase III trial, with a median progression-free survival of several years. These results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
$50 Billion • 25%
$60 Billion • 25%
$70 Billion • 25%
$80 Billion • 25%
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
Yes • 50%
No • 50%
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
Less than 500 million USD • 25%
500 million - 1 billion USD • 25%
1 billion - 2 billion USD • 25%
More than 2 billion USD • 25%
Amgen outperforms AstraZeneca • 33%
AstraZeneca outperforms Amgen • 33%
Both perform similarly • 34%